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Abstract: 
Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug 
(NSAID) for relief of inflammatory pain. A recent formulation combines this 
drug with hydroxypropyl-β-cyclodextrin (HPβCD) to improve its solubility 
and to enable subcutaneous administration. Previous studies confirmed the 
efficacy of this combination. This study’s aim was to evaluate the efficacy, 
safety and local tolerability of diclofenac HPβCD administered as a local 
submucosal injection prior to lower third molar surgery. We conducted a 
prospective, randomised, double-blind, placebo-controlled, parallel-group 
phase II single centre study. Seventy-five patients requiring mandibular 
third molar surgery were randomised into one of five groups: 5mg/1mL 
diclofenac HPβCD, 12.5mg/1mL diclofenac HPβCD, 25mg/1mL diclofenac 
HPβCD, 50mg/1mL diclofenac HPβCD or 1mL placebo. The respective study 
drug was injected into the mucosal tissue surrounding the surgical site 
prior to surgery following achievement of local anaesthesia. The primary 
outcome measure was the Area Under the Curve (AUC) of cumulative pain 
scores over the time from end of surgery to 6 hours post-surgery. This 
demonstrated a global treatment effect between the active groups and 
placebo, hence confirming the study drug’s efficacy (p=0.0126). Secondary 
outcome measures included the time until onset of pain and the time until 
patients required rescue medication, both showing statistical significance of 
the study drug compared to placebo (p<0.0161 and p<0.0001, 
respectively). The time until rescue medication ranged between 7.8hrs (for 
25mg/1mL diclofenac HPβCD) and 16hrs (for 50mg/1mL diclofenac 
http://mc.manuscriptcentral.com/jdr
Journal of Dental Research
For Peer Review
HPβCD). Interestingly, the 5mg/1mL solution appeared superior to the 
12.5mg/1mL and 25mg/1mL (time until rescue medication = 12.44hrs). A 
total of 14% of patients experienced minor Adverse Drug Reactions (ADRs) 
of which two cases demonstrated flap necrosis. These resolved without 
further intervention. The study results overall indicate efficacy, safety and 
relative tolerability of diclofenac HPβCD used locally as a submucosal 
injection prior to third molar surgery (ClinicalTrials.gov-Identifier: 
NCT01706588). 
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Abstract 
Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug (NSAID) 
for relief of inflammatory pain. A recent formulation combines this drug with 
hydroxypropyl-β-cyclodextrin (HPβCD) to improve its solubility and to enable 
subcutaneous administration. Previous studies confirmed the efficacy of this 
combination. This study’s aim was to evaluate the efficacy, safety and local 
tolerability of diclofenac HPβCD administered as a local submucosal injection prior 
to lower third molar surgery. We conducted a prospective, randomised, double-blind, 
placebo-controlled, parallel-group phase II single centre study. Seventy-five patients 
requiring mandibular third molar surgery were randomised into one of five groups: 
5mg/1mL diclofenac HPβCD, 12.5mg/1mL diclofenac HPβCD, 25mg/1mL 
diclofenac HPβCD, 50mg/1mL diclofenac HPβCD or 1mL placebo. The respective 
study drug was injected into the mucosal tissue surrounding the surgical site prior to 
surgery following achievement of local anaesthesia. The primary outcome measure 
was the Area Under the Curve (AUC) of cumulative pain scores over the time from 
end of surgery to 6 hours post-surgery. This demonstrated a global treatment effect 
between the active groups and placebo, hence confirming the study drug’s efficacy 
(p=0.0126). Secondary outcome measures included the time until onset of pain and 
the time until patients required rescue medication, both showing statistical 
significance of the study drug compared to placebo (p<0.0161 and p<0.0001, 
respectively). The time until rescue medication ranged between 7.8hrs (for 25mg/1mL 
diclofenac HPβCD) and 16hrs (for 50mg/1mL diclofenac HPβCD). Interestingly, the 
5mg/1mL solution appeared superior to the 12.5mg/1mL and 25mg/1mL (time until 
rescue medication = 12.44hrs). A total of 14% of patients experienced minor Adverse 
Drug Reactions (ADRs) of which two cases demonstrated flap necrosis. These 
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resolved without further intervention. The study results overall indicate efficacy, 
safety and relative tolerability of diclofenac HPβCD used locally as a submucosal 
injection prior to third molar surgery (ClinicalTrials.gov-Identifier: NCT01706588). 
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Introduction 
Diclofenac is a well-established non-selective non-steroidal anti-inflammatory drug 
(NSAID). Due to its anti-inflammatory, anti-pyretic and analgesic properties it is 
commonly used to treat acute/chronic pain, and inflammation (Barden et al. 2004; 
Blair and Plosker 2015; Gan 2010; Hersh et al. 2004; Moore 2007; Moore et al. 
2015c; Sengupta et al. 1985). Diclofenac sodium’s acidic form is poorly soluble 
(Sengupta et al. 1985) and therefore available as the sodium salt with 
pharmaceutically acceptable solvents, e.g.propylene glycol and benzyl alcohol to 
enable intramuscular (IM) and intravenous administration. Recent formulations use 
the complexing agent hydroxypropyl-β-cyclodextrin (HPβCD), serving as a solubility 
enhancer and facilitating smaller volumes for subcutaneous (SC) or submucosal 
application (Albers and Muller 1995; Blair and Plosker 2015), with previous studies 
confirming its successful and safe SC use (Chiarello et al. 2015; Dietrich et al. 2014; 
Zeitlinger et al. 2012).  
Local submucosal drug injection is well-established with local anaesthetics, but 
otherwise rarely used. The submucosal injection of dexamethasone (Chen et al. 2017; 
Moraschini et al. 2016; Saravanan et al. 2016) in the context of lower third molar 
(LM3) surgery is a notable exception. Submucosal injection of analgesics has been 
described with ketorolac in endodontic pain management (Penniston and Hargreaves 
1996) and tramadol in LM3 surgery (Ceccheti et al. 2014), combining the advantages 
of parenteral drug administration with an administration route that every dentist will 
be comfortable with. Both studies evaluated standard analgesic doses of the respective 
analgesic drug.  
However, we hypothesized that local submucosal injection of diclofenac may achieve 
analgesia at markedly lower than standard analgesic doses, taking advantage of high 
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concentrations locally at the site of tissue insult. This would be an attractive novel 
concept, potentially achieving analgesia while minimising side-effects. We planned 
the present study to meet two objectives; (i) to provide proof-of-principle or otherwise 
of low dose local analgesia and (ii) to evaluate the potential for submucosal 
diclofenac HPβCD as a pre-emptive analgesic in LM3 surgery, as this would have 
immediate clinical application, if effective. The aim of the present study was therefore 
to investigate the efficacy, local tolerability and safety of pre-emptive submucosal 
injection of different diclofenac HPβCD doses for postoperative analgesia in a phase-
II, proof-of-principle study.  
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Materials and Methods 
Study design 
This investigator-initiated trial was a prospective, randomised, double-blind, placebo-
controlled, parallel-group, phase-II single-centre study, conducted at The School of 
Dentistry, University of Birmingham and the Birmingham Dental Hospital, 
Birmingham, UK. Ethical approval was obtained by the Ethics Committee, Office for 
Research Ethics Committees Northern Ireland. The trial adhered to the Declaration of 
Helsinki and the International Conference on Harmonisation (IHC) consolidated 
Guideline on Good Clinical Practice (GCP). 
Patients (aged 18 to 65), referred for the surgical removal of a LM3 under local 
anaesthesia (LA) requiring osteotomy, were eligible to participate (please see online 
appendix for full list of inclusion/exclusion criteria). Written informed consent had to 
be provided to be enrolled.  
 
Intervention  
Patients received one of four diclofenac HPβCD (Akis®/Dicloin®, IBSA, Lugano, 
Switzerland) doses (50mg/1mL, 25mg/1mL, 12.5mg/1mL or 5mg/1mL), or 1ml 
placebo (sterile water, Appendix Figure 1).  
 
Randomisation, allocation concealment and blinding 
The investigational drug and preparation instructions were supplied packed in 
identical, sealed boxes, numbered sequentially according to a pre-defined, computer-
generated randomisation list in blocks of 10 (i.e., with two kits for each treatment 
dose level). No stratification was used. None of the investigators were aware of the 
randomisation method for the duration of the study to minimise risk of selection bias. 
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Following confirmation of all eligibility criteria on the surgery day, the next available 
randomisation number was allocated to the patient.  A single trained study-team 
member (PT), not involved in any other study procedure, opened the corresponding 
study medication pack and prepared the syringe for injection in a separate room. 
Placebo, 25mg and 50mg ampoules appeared identical; however, 5mg and 12.5mg 
formulations were prepared by diluting a 25mg ampoule with water for injection, with 
relevant instructions being contained in the medication pack. All 1mL syringes were 
delivered unmarked to the surgeon for administration. Neither the surgeon nor any 
other study-team member was made aware of its contents. 
 
Surgery and follow-up 
Experienced Oral Surgeons performed the LM3 removal within 30 days of the 
screening visit using a standard surgical protocol (see Appendix). The study 
medication was injected in three sites buccal to the LM3 (approximately equal 
distance apart, about 0.33mL per site), following achievement of LA. 
During the postoperative 6-hour-observational period at the investigational site pain 
measurements (using a 0-100mm Visual Analogue Scale (VAS)), the amount of 
rescue medication (RM) consumed (i.e.500mg paracetamol tablets) and surgical site 
appearance regarding bleeding, local irritancy/tolerability were recorded. Patients 
were then discharged and continued to make hourly pain ratings and recorded any RM 
intake in a postoperative diary for a further 6 hours. From the day after surgery, 
patients recorded the RM amount and an overall pain rating for each postoperative 
day (using a 0-100mm VAS) on a daily basis for one week. 
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Patients returned for two follow-up visits (=day 2 and 7 post-surgery) to assess 
postoperative extra-oral swelling, trismus and wound healing and verify RM 
consumption.  
Where required, extractions of any additional teeth were performed outside the trial. 
 
Baseline/Surgical Data 
A number of demographic, lifestyle and surgical data were collected at the respective 
study visits (see Appendix). 
 
Outcome measures and statistical analyses 
The primary endpoint was the Area Under the Curve (AUC) of pain scores over time 
(assessed using 0-100mm VAS), from end of surgery until 6 hours post-surgery 
compared between treatment groups.   
Assuming a standard deviation of 20mm and a mean difference (over the 6 hours) 
between groups of 25mm, a sample size of 12 patients per group would be required 
for two-by-two comparisons at α=0.05 and 80% power. Therefore, 15 patients per 
group were considered sufficient to preliminarily investigate the treatment’s efficacy.  
 
The following secondary endpoints were evaluated (see Appendix for further details):  
• AUC of pain scores over the 12-hour-observation period post-surgery 
• Time to onset of pain and time to RM 
• Extra-oral swelling and trismus 6 hours post-surgery, on day 2 and 7 
• Peak-Pain-Intensity and RM consumption 
• Cumulative proportions of patients using RM over the 6-hour-in-clinic-
observation period 
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• Adverse events 
 
Prespecified analysis plan 
Baseline/surgical characteristics were summarised by treatment group to evaluate 
whether the groups were balanced at randomisation, with mean/standard deviation 
used for continuous measures and number/percentage for categorical variables.  
Baseline characteristics were compared between the study groups using ANOVA 
models and Fisher’s exact test. 
Missing VAS pain scores or values after RM for the timed assessments in the 12h-
postoperative period were replaced by using a linear interpolation method. For this 
purpose, the linear trend between the last two valid VAS scores was used to replace 
the missing value. Patients’ pain ratings on postoperative days were not replaced, 
irrespective of timing of RM intake. 
Three populations were considered for analysis, Intention-To-Treat (ITT), Per-
Protocol (PP) and Safety Population (see Appendix for details). 
The primary endpoint analysis was conducted using both ITT and PP. Additionally to 
the unadjusted analyses, a multivariable analysis was performed, adjusting for BMI, 
amount of bone removal and gender in the ANOVA model. Post-hoc testing for 
pairwise comparisons between active and placebo groups did not adjust for multiple 
comparisons. 
All other endpoints were analysed using the ITT principle. Safety variables (AEs) 
were assessed using the Safety Population. 
Treatment effect estimates were reported with 95% confidence intervals and statistical 
tests performed at α=0.05.  
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Results 
We screened 80 patients between January and May 2013. Out of the 75 randomised 
patients, 15 each were allocated to the 5mg, 12.5mg and 25mg diclofenac HPβCD 
group, 14 to the 50mg HPβCD group and 16 to placebo (Appendix Figure 1).  
 
Protocol violations 
Two patients were excluded from the PP population due to major protocol violations, 
i.e.missing or delayed (=delay ≥15mins from scheduled time) pain measurements, 
which occurred in the 6-hour post-surgery period.  
 
Demographic/surgical characteristics 
Demographic and surgical characteristics were overall well-balanced between study 
groups (Table 1).  
 
Efficacy variables 
Primary outcome measure 
We found a global treatment effect in both ITT and PP populations (p=0.0126 and 
p=0.0057, respectively). In contrast, no statistically significant differences were found 
between the active study arms (Table 2, Figure 1).  
Adjustment for sex, BMI and amount of bone removal as covariates, also confirmed a 
global treatment effect between active and placebo arms (p=0.0188). Likewise, no 
statistically significant difference was noted between the diclofenac groups. Also, 
none of the covariates exerted an influence on the primary variable. 
 
Secondary outcome measures 
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The AUC of VAS scores over the 12-hour postoperative period revealed similar 
results to the 6-hour postoperative period with the Least Square Means (LSMs) being 
lower in the active groups compared with placebo (p=0.0471). A global treatment 
effect was seen between the diclofenac groups and placebo apart from the comparison 
between 25mg diclofenac HPβCD and placebo (p=0.1093). No statistically significant 
differences were observed between active treatment groups (Table 2, Figure 1).  
The active groups exhibited longer time until pain onset compared to placebo 
(p=0.0161 for overall treatment effect). Again, no statistical differences were found 
between diclofenac groups (Table 2, Figure 2).  
The time until first RM was significantly shorter in the placebo group compared to the 
active treatment groups, demonstrating again a global treatment effect (p<0.0001). 
Between the active groups no statistically significant differences were observed 
(Table 2, Figure 3). 
The cumulative proportion of patients taking RM over the 6-hour-period post-surgery 
was higher in placebo compared with the diclofenac groups (p=0.0483) (Table 2).   
Peak-Pain-Intensity analysis showed no global treatment effect (p=0.8595). Likewise, 
evaluation of trismus revealed no statistically significant differences between active 
groups and placebo, measured at 6 hours (p=0.1691), 2 days (p=0.5428) and 7 days 
(p=0.6260) post-surgery. Similar findings were observed for the extra-oral swelling 
measured at 6 hours (p=0.3855) and 2 days (p=0.5933). However, a global treatment 
effect was noted at 7 days after surgery, with a small but statistically significant 
difference in favour of the diclofenac groups compared to placebo (p=0.0214) (Table 
2).  
 
Safety/tolerability  
Page 13 of 43
http://mc.manuscriptcentral.com/jdr
Journal of Dental Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13 
 
AEs and Adverse Drug Reactions (ADRs=AEs occurring after injection of study drug 
and with causal relationship to study drug, as judged by investigator) were monitored 
throughout the study period. The causal relationship between AEs and the study drug 
was assessed at the time when the event occurred. 
The number of patients experiencing at least one AE was 8 (=53.3%) in the 5mg 
Diclofenac group, 9 (=60%) in the 12.5mg, 8 (=53.3%) in the 25mg and 5 (=35.7%) 
in the 50mg group. Six (=37.5%) AEs were reported amongst placebo patients 
(Appendix Table 1). The number of participants experiencing AEs did not differ 
significantly between groups. The most frequently occurring AEs were headache, 
vomiting and facial swelling (Appendix Table 2).  
The percentage of ADRs was 13.3% in both the 5mg and 12.5mg Diclofenac group, 
33.3% in the 25mg and 14.3% in the 50mg group. Placebo group patients did not 
report any ADRs (Appendix Table 1). The most frequent ADRs were injection site 
reactions, i.e.pain or swelling (Appendix Table 3). Two cases of flap necrosis were 
observed during the post-operative observation period. One mild ulceration arose in 
the 25mg group at the 2-day review appointment and one moderate ulceration was 
observed in the 50mg group at the 7-day review appointment (Appendix Figure 2 and 
3). These resolved spontaneously, without requiring any countermeasures. The 
number of ADRs did not differ significantly between groups.  
No Serious Adverse Events (SAEs) were recorded.  
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Discussion 
This trial aimed at evaluating the safety, tolerability and efficacy of varying doses of 
diclofenac HPβCD (5mg, 12.5mg, 25mg, 50mg) injected locally prior to LM3 
surgery.  
The choice of diclofenac sodium as an anti-inflammatory analgesic for relief of mild-
moderate dental pain is supported by (a)extensive studies reported from the Cochrane 
database (Barden et al. 2004; Moore 2007; Moore et al. 2015b; Moore et al. 2015c) 
showing this drug’s effectiveness in dental pain with low AE incidence encountered 
with other NSAIDs and analgesics (Gan 2010; Moore et al. 2015a); (b)rapid 
absorption from oral/parenteral preparations and other favourable pharmacokinetic 
properties (Sengupta et al. 1985) as well as its ability to accumulate into the 
cerebrospinal fluid and pain inhibition in the central nervous system (Bjorkman and 
Elam 1993; Kokki et al. 2008); and (c)its novel mechanism of analgesia involving 
selective effects on ion channels (Duan et al. 2012; Gwanyanya et al. 2012) quite 
separate from its well-known actions as a potent inhibitor of cyclo-oxygenases and 
inflammatory-pain-producing prostaglandins (Gan 2010; Rainsford 2015), 
lipoxygenases (Gan 2010),  nitric oxide-cGMP anti-nociceptive pathway activation 
and NMDA-receptor analgesia (Gan 2010). Some of these actions delineate 
diclofenac from other NSAIDs and may contribute to its potent effects as an acute 
pain-relieving drug. 
All four drug dose levels produced significantly superior effects compared with 
placebo in preventing pain during the 6-hour post-surgical observation period in terms 
of pain intensity levels, time until pain onset and time to first RM intake. The results 
are consistent with findings from previous studies showing the efficacy of the 
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parenterally administered sodium diclofenac HPβCD formulation (Blair and Plosker 
2015; Chiarello et al. 2015; Dietrich et al. 2014).  
No dose-dependent effects were observed in the four active groups in any of the 
evaluated endpoints. The lack of dose-dependency could be related to zero-order 
kinetics that may be apparent with the localised intra-mucosal delivery of high 
concentrations of the drugs. Zero-order kinetics have been observed with several 
drugs administered subcutaneously, including those from controlled-release systems 
(Cho et al. 1982; Hill et al. 2012; Liu et al. 2007; Mei et al. 2010).  Interestingly, the 
5mg dose demonstrated slightly better analgesic efficacy over the 6- and 12-hour 
postoperative evaluation period, although this was not significantly different from that 
observed with the other dose levels.  Also, the time until pain onset and RM was 
longer than in the 12.5mg and 25mg group.  The concept of locally/sub-mucosally 
injected analgesics is a fairly unexplored territory. The local pharmacokinetic profile 
of submucosal diclofenac HPβCD is not known. Comparing the pharmacodynamic 
responses involving pain relief in the present and previous studies (Dietrich et al. 
2014) with pharmacokinetic data is only possible in relation to the SC administration 
route of HPβCD diclofenac into the thigh. Thus, previous studies have shown 
essentially bioequivalence of 75mg/mL of this formulation hen given SC with that 
when given IM and similar to that with diclofenac sodium as Voltaren® given IM 
(Zeitlinger et al. 2012). The drug is rapidly absorbed with peak concentrations being 
achieved from SC and IM administration of HPβCD diclofenac at about 1hr, while 
those from IM diclofenac sodium were evident at 0.45hr suggesting that the HPβCD 
may act as a moderate slow-release system. The peak diclofenac concentrations from 
HPβCD diclofenac are slightly higher following IM compared with both SC 
administered drugs (Zeitlinger et al. 2012). Overall, however, both formulations 
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achieve similar absorption when administered as the sodium salt or the HPβCD 
formulation. The volumes of distribution, median residence time and elimination half-
life are comparable among the formulations and suggest that the drug is rapidly 
distributed and eliminated from both formulations. Therefore, an alternative 
explanation may be that in the context of the dental pain impaction model, a low dose 
of 5mg is as efficacious as the higher doses. However, topically applied solutions 
(e.g.Voltaren®) demonstrate a 10x delayed maximal plasma concentration (Altman et 
al. 2015), and if submucosal application showed a similarly delayed effect the here 
observed findings could be explained in this way. Furthermore, the vasoconstrictor in 
the LA, administered immediately before the submucosal diclofenac injection, may 
also have resulted in a delay of systemic distribution of the drug. Hence, the analgesic 
effects of submucosal diclofenac observed in the present study could be attributable to 
local or systemic drug effects, or a combination of both. 
We found no evidence for submucosal HPβCD diclofenac injection to have 
meaningful efficacy as a pre-emptive analgesic (i.e., having analgesic efficacy beyond 
5.5 half-lives), as there were no clinically important differences in terms of analgesic 
consumption or pain levels over the postoperative week (data not shown).  
We evaluated the submucosal HPβCD diclofenac’s efficacy in a modified (pre-
emptive) dental pain impaction model for several reasons. Firstly, we were interested 
in evaluating an approach that would be suitable for use in clinical practice, as LM3 
surgery is usually provided as an outpatient procedure and patients would not be able 
to inject themselves intra-orally postoperatively. Secondly, previous studies have 
shown that SC injections may cause some pain/discomfort, which would be 
minimised with a pre-emptive approach as it allowed submucosal injection following 
LA. 
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The main reported ADRs were injection site reactions, i.e.pain or swelling, reported in 
14.6% of active group patients, which concurs with previous evaluations (Blair and 
Plosker 2015; Dietrich et al. 2014); although this was somewhat surprising given that 
the injection was given following LA. Previous studies have shown that there were no 
serious adverse reactions following SC administration of sodium diclofenac HPβCD 
at three dose levels of 25, 50 and 75mg/mL (Dietrich et al. 2014; Zeitlinger et al. 
2012). Furthermore, Salomone et al.(Salomone et al. 2014) have shown that there are 
few subjects that showed local reactions to 50mg sodium diclofenac HPβCD at the 
injection sites in the abdomen, gluteus and quadriceps muscles, with all local 
reactions being mild-moderate and disappearing by 10mins (i.e.hardening) or 30mins 
(i.e.swelling and redness).  
In the present study, a flap necrosis was observed in two subjects, one in the 25mg 
and one in the 50mg group (Appendix Figures 2/3). These were highly unusual and 
not observed previously by the investigators in LM3 surgery. Both resolved without 
further interventions and without any sequelae. Among the rare adverse skin reactions 
that have been reported being associated with parenteral injection of diclofenac 
(Dadaci et al. 2015; Kilic et al. 2014; Nischal et al. 2009) and other drugs (Seremet et 
al. 2015), antibiotics (Alkan Bozkaya et al. 2016) and vaccines (Rygnestad and Kvam 
1995; Stefano et al. 2017; Wronecki and Czernik 1981) is the Nicolau syndrome 
(Livedoid dermatis or Embolia cutis medicamentosa). This was first reported in 1924 
by Freudenthal (James et al. 2015; Kilic et al. 2014; Nischal et al. 2009) and is a rare 
iatrogenic condition characterised by an immediate erythematous skin reaction 
following injection or ischaemic reaction (pallor) sometimes with a reticular pattern 
leading to necrosis of the skin and underlying tissue which can be severe and lead to 
disfigured scarring (James et al. 2015). We believe that the two occurrences of flap 
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necrosis could be unusual mucosal manifestations of Nicolau syndrome. Although 
previous reports on Nicolau syndrome have implicated diclofenac itself, we cannot 
rule out HPβCD as a possible cause. 
The results of the present study have to be cautiously interpreted due to the limited 
sample size of this phase-II study, which unsurprisingly resulted in some chance 
imbalances between groups in terms of patient and surgical characteristics. Thus, 
confounding by these and other unmeasured factors has to be considered.   
Overall, this study indicates efficacy, safety and relative tolerability of diclofenac 
HPβCD as a local submucosal analgesic. The study provides evidence in support of 
the novel concept of low-dose local analgesia for the first time. Further studies should 
include investigation of the study drug’s local pharmacokinetics, and larger phase-III 
trials are required to confirm efficacy and safety of low-dose submucosal analgesia 
for acute pain management.  
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Figure legends 
 
Figure 1 – Pain intensity over time 
Pain intensity of the respective study groups from end of surgery until 12 hours post-
surgery 
VAS = Visual Analogue Scale 
 
Figure 2 – Time to pain onset 
Kaplan Meier survival curve demonstrating the time until onset of pain following 
surgery in the respective study groups 
 
Figure 3 – Time to first rescue medication 
Kaplan Meier survival curve illustrating the time until the first rescue medication was 
consumed postoperatively in the respective study groups 
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Table 1 – Baseline demographic and surgical characteristics; Continuous variables are 
presented as mean (SD)
c
. 
 
a
 BMI = Body Mass Index 
b
 LA = Local anaesthetic 
c 
SD = Standard Deviation 
 5mg 
(n=15) 
12.5mg 
(n=15) 
25mg 
(n=15) 
50mg 
(n=14) 
Placebo 
(n=16) 
Age (years) 
28.33 
(7.32) 
 
27.73 
(9.35) 
 
29.73 
(9.00) 
 
27.36 
(4.52) 
 
29.81 
(9.54) 
 
Male (%) 40 60 20 43 25 
BMI
a 
27.46 
(6.50) 
 
24.56 
(3.98) 
 
24.11 
(4.10) 
 
27.05 
(6.43) 
 
24.47 
(4.26) 
 
Ethnicity (%)      
Caucasian 53 47 60 93 50 
Black 20 20 7 0 6 
Asian 27 33 26 7 31 
Other 0 0 7 0 13 
Preoperative LA
b
 dose (ml) 
5.78 
(0.98) 
 
5.72 
(1.04) 
 
5.29 
(1.21) 
 
5.67 
(1.22) 
 
5.70 
(1.08) 
 
Supplemental LA (%) 7 7 27 0 6 
Bone removal (%)      
Minor 33 33 40 50 44 
Moderate 60 47 53 43 44 
Severe 7 20 7 7 12 
Duration of surgery (mins) 
12.93 
(5.85) 
 
14.20 
(6.74) 
 
10.07 
(5.11) 
 
11.64 
(6.48) 
 
10.81 
(5.11) 
 
Tooth sectioning (%) 67 67 40 57 50 
Lingual flap (%) 20 40 13 36 38 
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 5mg 
(n=15) 
12.5mg 
(n=15) 
25mg 
(n=15) 
50mg 
(n=14) 
Placebo 
(n=16) 
p-value$ 
VASa pain/ 
AUCb 0-6hrs 
(LSMsc, ITTd 
population), 
mean (SDe) 
6843 
(6259) 
8833 
(6331) 
9998 
(8080) 
7290 
(6509) 
15539 
(9280) 
0.0126 
p-value # 0.0017 0.0144 0.0417 0.0034   
VASa pain/ 
AUC
b
 0-6hrs 
(LSMsc, ITTd 
population, 
multivariable 
ANOVA*), 
adjusted mean  
6978 9985 10112 7733 15582 0.0188 
p-value # 0.0020 0.0394 0.0388 0.0049   
VAS pain / 
AUC 0-6hrs 
(LSMs, PPf 
population), 
mean (SD) 
5836 
(5079) 
8833 
(6331) 
10339 
(8273) 
7290 
(6509) 
15539 
(9280) 
0.0057 
p-value # 0.0005 0.0129 0.0559 0.0029  
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VAS pain/ 
AUC 0-12hrs 
(LSMs, ITT 
population), 
mean (SD) 
22848 
(19947) 
29481 
(17573) 
32197 
(20729) 
25770 
(20104) 
43890 
(21606) 
0.0471 
p-value # 0.0047 0.0495 0.1093 0.0160   
Time to pain 
onset (hrs), 
mean (SD) 
5.88 (5.86) 
4.53 
(5.69) 
2.88 (2.51) 
9.69 
(18.90) 
1.91 (1.07) 0.0161 
Time to first 
rese 
medication 
(hr, mean 
(SD) 
12.44 
(10.24) 
9.03 
(9.08) 
7.81 (8.46) 
16.05 
(18.81) 
2.63 (0.53) <0.0001 
Number of 
patients 
using rescue 
medication at 
0-6hrs (%) 
40 53 73 50 88 
 
 
0.0483 
VAS Peak 
Pain 
Intensity, 
mean (SD) 
33.20 
(21.24) 
36.20 
(14.73) 
33.53 
(16.58) 
35.43 
(21.54) 
41.06 
(30.81) 
0.8595 
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Interincisal 
distance, day 
2 (mm), 
mean (SD) 
24.00 
(6.89) 
28.00 
(6.78) 
26.80 
(9.86) 
28.29 
(6.76) 
26.69 
(8.95) 
0.5428 
Interincisal 
distance, day 
7 (mm), 
mean (SD) 
32.20 
(7.16) 
33.33 
(7.98) 
29.47 
(8.74) 
31.86 
(6.40) 
35.00 
(8.69) 
0.6260 
Swelling, 
day 2 (cm), 
mean (SD) 
15.18 
(0.95) 
15.43 
(0.73) 
15.09 
(0.86) 
15.61 
(0.95) 
15.07 
(0.87) 
0.5933 
Swelling day 
7 (cm), mean 
(SD) 
14.92 
(1.07) 
15.29 
(0.82) 
14.93 
(0.91) 
15.47 
(0.90) 
14.87 
(0.83) 
0.0214 
 
 
Continuous variables are presented as mean (SD). 
The primary outcome variable (VAS score AUC 0-6hrs post-surgery) was evaluated in the 
ITT and PP population. 
Interincisal distance was measured in mm and represents the distance between left upper and 
lower incisor at maximal mouth opening.  
Swelling represents the tragus to chin distance in cm. 
 
# P-value for pairwise comparison between active group and placebo 
$ global p-value for treatment effect (ANOVA) 
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* Multivariate ANOVA included Body Mass Index (BMI), gender and amount of bone 
removal as covariates  
 
a VAS = Visual Analogue Scale 
b AUC = Area Under the Curve 
c
 LSMs = Least Square Means 
d ITT = Intention To Treat 
e SD = Standard Deviation 
f PP = Per Protocol 
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Figure 1 – Pain intensity over time 
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Figure 2 – Time to pain onset 
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Figure 3 – Time until first rescue medication 
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Supplemental Material, Gorecki et al. 1
Submucosal Diclofenac for Acute Postoperative Pain in Third Molar Surgery: A randomized 
controlled clinical trial 
 
Patricia Gorecki, Kim D. Rainsford, Pankaj Taneja, Yogesh Bulsara, David Pearson, Daniel 
Saund, Bilal Ahmed, Thomas Dietrich 
 
Methods 
 
Exclusion criteria 
Females of childbearing potential were required to have a negative urine pregnancy test at 
the inclusion visit and be using an appropriate contraception method throughout the study 
period.  
The following exclusion criteria applied: 
• Patients refusing to give written informed consent or to return for control visits 
• Patients enrolled in a clinical trial in the previous 3 months 
• Pregnant or breast-feeding women 
• Patients with an allergy to diclofenac/other NSAIDs 
• Patients on medication that could affect the efficacy and/or safety outcomes 
assessed in this trial, e.g. corticosteroids, other NSAIDs, anticoagulant/antiplatelet 
agents or antimicrobials.  
• Patients with a history of gastrointestinal disorders, coagulation disorders, 
hepatic/renal/cardiac impairment, peripheral arterial disease or uncontrolled 
hypertension 
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Supplemental Material, Gorecki et al. 2
• Patients with major psychiatric disorders compromising study participation in the 
investigator’s opinion 
• Alcohol or drug abuse in the previous 12 months 
 
Surgery and follow-up 
Patients received an appointment for their LM3 removal within 30 days of their screening 
visit. Lidocaine 2% with 1:80.000 epinephrine (Septodont, Maidstone, Kent, UK) was used 
for LA (administered as an inferior dental nerve block and buccal infiltration). The maximum 
allowed dose of 8.8mL included intraoperative supplemental administration, if necessary. 
Once LA was achieved a 1mL submucosal injection of the study medication was given in 
three sites (approximately equal distance apart) buccal to the third molar area, with about 
0.33mL given per site.  
Experienced oral surgeons performed the surgery using a standard surgical procedure. A 
muco-periosteal envelope or triangular flap was raised according to the surgeon’s 
preference, bone removal and tooth sectioning was performed using a surgical hand-piece 
and burs as required, the respective tooth was elevated and interrupted sutures were 
placed to achieve wound closure (Vicryl Rapide®, Ethicon, Johnson & Johnson Medical Ltd., 
Norderstedt, Germany).  
Following surgery patients received standard postoperative instructions and stayed at the 
investigational site for 6 hours for the assessment of pain (using a 0-100mm Visual Analogue 
Scale (VAS)), the amount of rescue medication consumed (i.e. 500mg paracetamol tablets) 
and the appearance of the surgical site regarding bleeding and assessment of the local 
irritancy and tolerability.  After the observational period participants were discharged with a 
box of paracetamol and a postoperative diary to record their pain levels, analgesic and other 
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Supplemental Material, Gorecki et al. 3
concomitant medication consumption and adverse events (AEs) on a daily basis for one 
week.  
Patients were asked to return for two follow-up visits on day 2 and 7 after surgery (=visits 3 
and 4) during which post-surgical extra-oral swelling and trismus, as well as wound healing 
were assessed and rescue medication consumption was verified.   
 
Baseline/Surgical Data 
Demographic and lifestyle data were collected at the screening visit, including age, gender, 
ethnicity, weight, height and Body Mass Index (BMI). On the day of surgery some surgical 
measurements were collected, i.e. which LM3 was removed (left/right), whether the tooth 
was removed completely (yes/no), preoperative LA dose (in mL), supplemental LA dose (in 
mL), amount of bone removal (minor/moderate/severe), tooth sectioning (yes/no), raising 
of lingual flap (yes/no) and duration of surgery (in min).  
 
 
Prespecified analysis plan 
• Intention-To-Treat (ITT)= all randomised patients receiving ≥one study medication 
dose and with ≥one post-baseline efficacy evaluation; 
• Per-Protocol (PP)= all ITT population patients without major protocol violation; 
• Safety Population= all randomised patients receiving the study intervention. 
 
Outcome measures and statistical analyses 
The following secondary endpoints were evaluated:  
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• AUC of pain scores over the 12-hour-observation period post-surgery (assessed at 
the end of surgery, at 15mins intervals for the 6-hour-observation period on clinic 
and hourly for 6 hours after discharge), using an ANOVA model; 
• Time to onset of pain (=pain ≥30mm on VAS) and time to RM, using survival analysis; 
• Extra-oral swelling (=distance between lower border of tragus and a point in the 
midline, 3cm below vermilion border of lower lip, marked in removable ink on 
patient’s chin) and trismus (=distance between left upper and lower incisor at 
maximal opening, assessed using a ruler) 6 hours post-surgery, on day 2 and day 7, 
using an ANOVA model; 
• Peak-Pain-Intensity (=highest pain intensity during the 12-hour-observation period 
post-surgery) and RM consumption, using an ANOVA model; 
• Cumulative proportions of patients using RM over the 6-hour-in-clinic-observation 
period, using chi-square test; 
• AE comparisons (reported as description of event, intensity (mild/moderate/severe), 
seriousness (serious/non-serious), date of onset/end, expectation 
(expected/unexpected) and correlation with study treatment 
(certain/probable/possible/unlikely/not related/not assessable)), using Fisher’s exact 
test. 
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Results: 
Appendix Table 1: AEs and ADRs occurring after injection of study medication (safety population)  
Variable 5mg 
(n=15) 
12.5mg 
(n=15) 
25mg 
(n=15) 
50mg 
(n=14) 
Placebo 
(n=16) 
Total 
(n=75) 
 
Adverse Events (AEs
a
) 
Total number of AEs 23 20 25 9 15 92 
Patients with at least one AE, N (%) 8 (53.3%) 9 (60%) 8 (53.3%) 5 (35.7%) 6 (37.5%) 36 (48%) 
 
Adverse Drug reactions (ADRs
b
) 
Total number of ADRs 2 3 9 2 0 16 
Patients with ADRs, N (%) 2 (13.3%) 2 (13.3%) 5 (33.3%) 2 (14.3%) 0 (0%) 11 (14.6%) 
 
a
 AEs = Adverse Event 
b 
ADRs = Adverse Drug Reaction 
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Appendix Table 2: AEs classified by PT (=preferred patient term) 
 
AE
a
 description 
5mg 
n=15 
12.5mg 
n=15 
25mg 
n=15 
50mg 
n=14 
Placebo 
n=16 
Diarrhoea, N (%) 1 (7%) 0 0 0 1 (6%) 
Nausea, N (%) 1 (7%) 0 0 1 (7%) 2 (13%) 
Vomiting, N (%) 2 (13%) 1 (7%) 2 (13%) 0 1 (6%) 
Dizziness, N (%) 0 1 (7%) 1 (7%) 0 0 
Headache, N (%) 4 (27%) 1 (7%) 2 (13%) 1 (7%) 2 (13%) 
Jaw pain, N (%) 1 (7%) 4 (27%) 0 0 2 (13%) 
Injection site pain, N (%) 2 (13%) 2 (13%) 5 (33%) 1 (7%) 0 
(Injection site) swelling, N (%) 2 (13%) 0 2 (13%) 0 0 
Flap necrosis, N (%) 0 0 1 (7%) 1 (7%) 0 
Wound infection, N (%) 1 (7%) 1 (7%) 1 (7%) 0 1 (6%) 
Gingival bleeding, N (%) 1 (7%) 0 1 (7%) 0 0 
 
a
 AE = Adverse Event 
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Appendix Table 3: ADRs classified by PT (=preferred patient term) 
 
ADR
a
 description 5mg 
n=15 
12.5mg 
n=15 
25mg 
n=15 
50mg 
n=14 
Placebo 
n=16 
Flap necrosis, N (%) 0 0 1 (7%) 1 (7%) 0 
Injection site pain, N (%) 2 (13%) 2 (13%) 5 (33%) 1 (7%) 0 
Injection site swelling, N (%) 0 0 2 (13%) 0 0 
 
a
 ADR = Adverse Drug Reaction 
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Supplementary Figure 1: Study Consort Flow Diagram 
Eighty patients were screened for eligibility, out of which 75 were randomised and completed 
the randomised controlled trial.  
Assessed for eligibility (n=80) 
Excluded (n=5) 
♦   Not meeting inclusion criteria or 
♦   Declined to participate 
 
5mg HPBCD 
n=15 
 
Allocation 
Surgery visit =Visit 1 
 
Follow-Up Day7 
Final study visit =Visit 3 
Follow-Up Day2 
=Visit 2 
Randomized (n=75) 
Enrollment 
Screening visit =Visit 0 
12.5mg HPBCD 
n=15 
 
25mg HPBCD 
n=15 
 
50mg HPBCD 
n=14 
 
1mL placebo 
n=16 
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Supplementary Figure 2: Partial flap necrosis in the 25mg/1mL HPβCD
1
 diclofenac group, 
evident at 2-day review.  
The patient was completely asymptomatic. The necrosis was present around the margins of 
the mucoperiosteal flap. This resolved without further intervention by the 7-day post-
operative review appointment. 
1 
HPβCD - hydroxypropyl-β-cyclodextrin 
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Supplementary Figure 3: Partial flap necrosis in the 50mg/1mL HPβCD dicolfenac group 
evident at 7-day review. 
The patient was asymptomatic and the necrosis recovered without further intervention 
(similar to the necrosis seen in the 25mg/1mL group – see Appendix Figure 2).  
1 
HPβCD - hydroxypropyl-β-cyclodextrin 
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 3, 4 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 5, 6 
2b Specific objectives or hypotheses 5, 6 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 7 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A  
Participants 4a Eligibility criteria for participants 7, Appendix 
4b Settings and locations where the data were collected 7 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
7, 8 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
9, 10 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 9 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 7, 8 
8b Type of randomisation; details of any restriction (such as blocking and block size) 7 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
7, 8 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
7, 8 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 7, 8 
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assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 8 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9 - 11 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
12 
13b For each group, losses and exclusions after randomisation, together with reasons 12 
Recruitment 14a Dates defining the periods of recruitment and follow-up 12 
14b Why the trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
12 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
12, 13, Table 
2 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Table 2 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
12 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 14, Suppl. 
Tables 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 16-19 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 15-19 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 15-19 
Other information  
Registration 23 Registration number and name of trial registry 2, 4 
Protocol 24 Where the full trial protocol can be accessed, if available N/A 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 2, 20 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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